Tamrintamab pamozirine

DB17222InvestigationalProtein Based Therapies

Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3.

Code names
SC-003

Resolves to

Compound
UNIIGM0RU5SU0ECAS2148334-68-1

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Tamrintamab pamozirine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In